Maintenance dose calculations[1]

Please see Preparation and Administration of COSENTYX® for Intravenous Use under the DOSAGE AND ADMINISTRATION section in the full Prescribing Information.

Cosentyx® (secukinumab)

Weight (lb)	Weight (kg) (lb x 0.453592)*	Total dose (mg) (kg x 1.75 mg/kg)†	Number of single-use vials required	Total volume to be withdrawn (mL) (Total dose x 5 mL/125 mg)†
85	38.56	67.5	1	2.7
86	39.01	68.3	1	2.7
87	39.46	69.1	1	2.8
88	39.92	69.9	1	2.8
89	40.37	70.6	1	2.8
90	40.82	71.4	1	2.9
91	41.28	72.2	1	2.9
92	41.73	73.0	1	2.9
93	42.18	73.8	1	3.0
94	42.64	74.6	1	3.0
95	43.09	75.4	1	3.0
96	43.54	76.2	1	3.0
97	44.00	77.0	1	3.1
98	44.45	77.8	1	3.1
99	44.91	78.6	1	3.1
100	45.36	79.4	1	3.2
101	45.81	80.2	1	3.2
102	46.27	81.0	1	3.2
103	46.72	81.8	1	3.3
104	47.17	82.6	1	3.3
105	47.63	83.3	1	3.3
106	48.08	84.1	1	3.4
107	48.53	84.9	1	3.4
108	48.99	85.7	1	3.4
109	49.44	86.5	1	3.5
110	49.90	87.3	1	3.5
111	50.35	88.1	1	3.5
112	50.80	88.9	1	3.6
113	51.26	89.7	1	3.6
114	51.71	90.5	1	3.6
115	52.16	91.3	1	3.7
116	52.62	92.1	1	3.7
117	53.07	92.9	1	3.7
118	53.52	93.7	1	3.7
119	53.98	94.5	1	3.8
120	54.43	95.3	1	3.8
121	54.88	96.0	1	3.8
122	55.34	96.8	1	3.9
123	55.79	97.6	1	3.9
124	56.25	98.4	1	3.9
125	56.70	99.2	1	4.0
126	57.15	100.0	1	4.0
127	57.61	100.8	1	4.0
128	58.06	101.6	1	4.1
129	58.51	102.4	1	4.1
130	58.97	103.2	1	4.1

*Rounded to the nearest hundredth decimal place.

†Rounded to the nearest tenth decimal place.

Total doses exceeding 300 mg per infusion are not recommended for the 1.75-mg/kg maintenance dose in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), or non-radiographic axial spondyloarthritis (nr-axSpA).

COSENTYX IV formulation may be administered with or without a loading dose.

In using this guide, you are agreeing to the following: This guide is intended for use by qualified healthcare providers only and is not a substitute for clinical judgment. Novartis Pharmaceuticals Corporation makes no claims pertaining to the accuracy of the information contained within the guide. All calculations should be confirmed prior to administration of COSENTYX for IV use. Neither Novartis Pharmaceuticals Corporation nor any party involved in the creation of this website is liable to you or others for any actions taken or decisions made in reliance on this guide.

IV, intravenous.

Please see Indications and Important Safety Information on page 8.

Please see full Prescribing Information, including Medication Guide.

Maintenance dose calculations[1] (cont)

Please see Preparation and Administration of COSENTYX® for Intravenous Use under the DOSAGE AND ADMINISTRATION section in the full Prescribing Information.

Cosentyx® (secukinumab)

Weight (lb)	Weight (kg) (lb x 0.453592)*	Total dose (mg) (kg x 1.75 mg/kg)†	Number of single-use vials required	Total volume to be withdrawn (mL) (Total dose x 5 mL/125 mg)†
131	59.42	104.0	1	4.2
132	59.87	104.8	1	4.2
133	60.33	105.6	1	4.2
134	60.78	106.4	1	4.3
135	61.23	107.2	1	4.3
136	61.69	108.0	1	4.3
137	62.14	108.7	1	4.3
138	62.60	109.5	1	4.4
139	63.05	110.3	1	4.4
140	63.50	111.1	1	4.4
141	63.96	111.9	1	4.5
142	64.41	112.7	1	4.5
143	64.86	113.5	1	4.5
144	65.32	114.3	1	4.6
145	65.77	115.1	1	4.6
146	66.22	115.9	1	4.6
147	66.68	116.7	1	4.7
148	67.13	117.5	1	4.7
149	67.59	118.3	1	4.7
150	68.04	119.1	1	4.8
151	68.49	119.9	1	4.8
152	68.95	120.7	1	4.8
153	69.40	121.4	1	4.9
154	69.85	122.2	1	4.9
155	70.31	123.0	1	4.9
156	70.76	123.8	1	5.0
157	71.21	124.6	1	5.0
158	71.67	125.4	1	5.0
159	72.12	126.2	1	5.0
160	72.57	127.0	2	5.1
161	73.03	127.8	2	5.1
162	73.48	128.6	2	5.1
163	73.94	129.4	2	5.2
164	74.39	130.2	2	5.2
165	74.84	131.0	2	5.2
166	75.30	131.8	2	5.3
167	75.75	132.6	2	5.3
168	76.20	133.4	2	5.3
169	76.66	134.1	2	5.4
170	77.11	134.9	2	5.4
171	77.56	135.7	2	5.4
172	78.02	136.5	2	5.5
173	78.47	137.3	2	5.5
174	78.93	138.1	2	5.5
175	79.38	138.9	2	5.6
176	79.83	139.7	2	5.6

*Rounded to the nearest hundredth decimal place.

†Rounded to the nearest tenth decimal place.

Total doses exceeding 300 mg per infusion are not recommended for the 1.75-mg/kg maintenance dose in adults with PsA, AS, or nr-axSpA.

COSENTYX IV formulation may be administered with or without a loading dose.

In using this guide, you are agreeing to the following: This guide is intended for use by qualified healthcare providers only and is not a substitute for clinical judgment. Novartis Pharmaceuticals Corporation makes no claims pertaining to the accuracy of the information contained within the guide. All calculations should be confirmed prior to administration of COSENTYX for IV use. Neither Novartis Pharmaceuticals Corporation nor any party involved in the creation of this website is liable to you or others for any actions taken or decisions made in reliance on this guide.

Please see Indications and Important Safety Information on page 8.

Please see full Prescribing Information, including Medication Guide.

Maintenance dose calculations[1] (cont)

Please see Preparation and Administration of COSENTYX® for Intravenous Use under the DOSAGE AND ADMINISTRATION section in the full Prescribing Information.

Cosentyx® (secukinumab)

Weight (lb)	Weight (kg) (lb x 0.453592)*	Total dose (mg) (kg x 1.75 mg/kg)†	Number of single-use vials required	Total volume to be withdrawn (mL) (Total dose x 5 mL/125 mg)†
177	80.29	140.5	2	5.6
178	80.74	141.3	2	5.7
179	81.19	142.1	2	5.7
180	81.65	142.9	2	5.7
181	82.10	143.7	2	5.7
182	82.55	144.5	2	5.8
183	83.01	145.3	2	5.8
184	83.46	146.1	2	5.8
185	83.91	146.9	2	5.9
186	84.37	147.6	2	5.9
187	84.82	148.4	2	5.9
188	85.28	149.2	2	6.0
189	85.73	150.0	2	6.0
190	86.18	150.8	2	6.0
191	86.64	151.6	2	6.1
192	87.09	152.4	2	6.1
193	87.54	153.2	2	6.1
194	88.00	154.0	2	6.2
195	88.45	154.8	2	6.2
196	88.90	155.6	2	6.2
197	89.36	156.4	2	6.3
198	89.81	157.2	2	6.3
199	90.26	158.0	2	6.3
200	90.72	158.8	2	6.4
201	91.17	159.6	2	6.4
202	91.63	160.3	2	6.4
203	92.08	161.1	2	6.4
204	92.53	161.9	2	6.5
205	92.99	162.7	2	6.5
206	93.44	163.5	2	6.5
207	93.89	164.3	2	6.6
208	94.35	165.1	2	6.6
209	94.80	165.9	2	6.6
210	95.25	166.7	2	6.7
211	95.71	167.5	2	6.7
212	96.16	168.3	2	6.7
213	96.62	169.1	2	6.8
214	97.07	169.9	2	6.8
215	97.52	170.7	2	6.8
216	97.98	171.5	2	6.9
217	98.43	172.3	2	6.9
218	98.88	173.0	2	6.9
219	99.34	173.8	2	7.0
220	99.79	174.6	2	7.0
221	100.24	175.4	2	7.0
222	100.70	176.2	2	7.0

*Rounded to the nearest hundredth decimal place.

†Rounded to the nearest tenth decimal place.

Total doses exceeding 300 mg per infusion are not recommended for the 1.75-mg/kg maintenance dose in adults with PsA, AS, or nr-axSpA.

COSENTYX IV formulation may be administered with or without a loading dose.

In using this guide, you are agreeing to the following: This guide is intended for use by qualified healthcare providers only and is not a substitute for clinical judgment. Novartis Pharmaceuticals Corporation makes no claims pertaining to the accuracy of the information contained within the guide. All calculations should be confirmed prior to administration of COSENTYX for IV use. Neither Novartis Pharmaceuticals Corporation nor any party involved in the creation of this website is liable to you or others for any actions taken or decisions made in reliance on this guide.

Please see Indications and Important Safety Information on page 8.

Please see full Prescribing Information, including Medication Guide.

Maintenance dose calculations[1] (cont)

Please see Preparation and Administration of COSENTYX® for Intravenous Use under the DOSAGE AND ADMINISTRATION section in the full Prescribing Information.

Cosentyx® (secukinumab)

Weight (lb)	Weight (kg) (lb x 0.453592)*	Total dose (mg) (kg x 1.75 mg/kg)†	Number of single-use vials required	Total volume to be withdrawn (mL) (Total dose x 5 mL/125 mg)†
223	101.15	177.0	2	7.1
224	101.60	177.8	2	7.1
225	102.06	178.6	2	7.1
226	102.51	179.4	2	7.2
227	102.97	180.2	2	7.2
228	103.42	181.0	2	7.2
229	103.87	181.8	2	7.3
230	104.33	182.6	2	7.3
231	104.78	183.4	2	7.3
232	105.23	184.2	2	7.4
233	105.69	185.0	2	7.4
234	106.14	185.7	2	7.4
235	106.59	186.5	2	7.5
236	107.05	187.3	2	7.5
237	107.50	188.1	2	7.5
238	107.95	188.9	2	7.6
239	108.41	189.7	2	7.6
240	108.86	190.5	2	7.6
241	109.32	191.3	2	7.7
242	109.77	192.1	2	7.7
243	110.22	192.9	2	7.7
244	110.68	193.7	2	7.7
245	111.13	194.5	2	7.8
246	111.58	195.3	2	7.8
247	112.04	196.1	2	7.8
248	112.49	196.9	2	7.9
249	112.94	197.7	2	7.9
250	113.40	198.4	2	7.9
251	113.85	199.2	2	8.0
252	114.31	200.0	2	8.0
253	114.76	200.8	2	8.0
254	115.21	201.6	2	8.1
255	115.67	202.4	2	8.1
256	116.12	203.2	2	8.1
257	116.57	204.0	2	8.2
258	117.03	204.8	2	8.2
259	117.48	205.6	2	8.2
260	117.93	206.4	2	8.3
261	118.39	207.2	2	8.3
262	118.84	208.0	2	8.3
263	119.29	208.8	2	8.4
264	119.75	209.6	2	8.4
265	120.20	210.4	2	8.4
266	120.66	211.1	2	8.4
267	121.11	211.9	2	8.5
268	121.56	212.7	2	8.5

*Rounded to the nearest hundredth decimal place.

†Rounded to the nearest tenth decimal place.

COSENTYX IV formulation may be administered with or without a loading dose.

Total doses exceeding 300 mg per infusion are not recommended for the 1.75-mg/kg maintenance dose in adults with PsA, AS, or nr-axSpA.

In using this guide, you are agreeing to the following: This guide is intended for use by qualified healthcare providers only and is not a substitute for clinical judgment. Novartis Pharmaceuticals Corporation makes no claims pertaining to the accuracy of the information contained within the guide. All calculations should be confirmed prior to administration of COSENTYX for IV use. Neither Novartis Pharmaceuticals Corporation nor any party involved in the creation of this website is liable to you or others for any actions taken or decisions made in reliance on this guide.

Please see Indications and Important Safety Information on page 8.

Please see full Prescribing Information, including Medication Guide.

Maintenance dose calculations[1] (cont)

Please see Preparation and Administration of COSENTYX® for Intravenous Use under the DOSAGE AND ADMINISTRATION section in the full Prescribing Information.

Cosentyx® (secukinumab)

Weight (lb)	Weight (kg) (lb x 0.453592)*	Total dose (mg) (kg x 1.75 mg/kg)†	Number of single-use vials required	Total volume to be withdrawn (mL) (Total dose x 5 mL/125 mg)†
269	122.02	213.5	2	8.5
270	122.47	214.3	2	8.6
271	122.92	215.1	2	8.6
272	123.38	215.9	2	8.6
273	123.83	216.7	2	8.7
274	124.28	217.5	2	8.7
275	124.74	218.3	2	8.7
276	125.19	219.1	2	8.8
277	125.64	219.9	2	8.8
278	126.10	220.7	2	8.8
279	126.55	221.5	2	8.9
280	127.01	222.3	2	8.9
281	127.46	223.1	2	8.9
282	127.91	223.8	2	9.0
283	128.37	224.6	2	9.0
284	128.82	225.4	2	9.0
285	129.27	226.2	2	9.0
286	129.73	227.0	2	9.1
287	130.18	227.8	2	9.1
288	130.63	228.6	2	9.1
289	131.09	229.4	2	9.2
290	131.54	230.2	2	9.2
291	132.00	231.0	2	9.2
292	132.45	231.8	2	9.3
293	132.90	232.6	2	9.3
294	133.36	233.4	2	9.3
295	133.81	234.2	2	9.4
296	134.26	235.0	2	9.4
297	134.72	235.8	2	9.4
298	135.17	236.5	2	9.5
299	135.62	237.3	2	9.5
300	136.08	238.1	2	9.5
301	136.53	238.9	2	9.6
302	136.98	239.7	2	9.6
303	137.44	240.5	2	9.6
304	137.89	241.3	2	9.7
305	138.35	242.1	2	9.7
306	138.80	242.9	2	9.7
307	139.25	243.7	2	9.7
308	139.71	244.5	2	9.8
309	140.16	245.3	2	9.8
310	140.61	246.1	2	9.8
311	141.07	246.9	2	9.9
312	141.52	247.7	2	9.9
313	141.97	248.5	2	9.9
314	142.43	249.2	2	10.0

*Rounded to the nearest hundredth decimal place.

†Rounded to the nearest tenth decimal place.

COSENTYX IV formulation may be administered with or without a loading dose.

Total doses exceeding 300 mg per infusion are not recommended for the 1.75-mg/kg maintenance dose in adults with PsA, AS, or nr-axSpA.

In using this guide, you are agreeing to the following: This guide is intended for use by qualified healthcare providers only and is not a substitute for clinical judgment. Novartis Pharmaceuticals Corporation makes no claims pertaining to the accuracy of the information contained within the guide. All calculations should be confirmed prior to administration of COSENTYX for IV use. Neither Novartis Pharmaceuticals Corporation nor any party involved in the creation of this website is liable to you or others for any actions taken or decisions made in reliance on this guide.

Please see Indications and Important Safety Information on page 8.

Please see full Prescribing Information, including Medication Guide.

Maintenance dose calculations[1] (cont)

Please see Preparation and Administration of COSENTYX® for Intravenous Use under the DOSAGE AND ADMINISTRATION section in the full Prescribing Information.

Cosentyx® (secukinumab)

Weight (lb)	Weight (kg) (lb x 0.453592)*	Total dose (mg) (kg x 1.75 mg/kg)†	Number of single-use vials required	Total volume to be withdrawn (mL) (Total dose x 5 mL/125 mg)†
315	142.88	250.0	2	10.0
316	143.34	250.8	2	10.0
317	143.79	251.6	3	10.1
318	144.24	252.4	3	10.1
319	144.70	253.2	3	10.1
320	145.15	254.0	3	10.2
321	145.60	254.8	3	10.2
322	146.06	255.6	3	10.2
323	146.51	256.4	3	10.3
324	146.96	257.2	3	10.3
325	147.42	258.0	3	10.3
326	147.87	258.8	3	10.4
327	148.32	259.6	3	10.4
328	148.78	260.4	3	10.4
329	149.23	261.2	3	10.4
330	149.69	261.9	3	10.5
331	150.14	262.7	3	10.5
332	150.59	263.5	3	10.5
333	151.05	264.3	3	10.6
334	151.50	265.1	3	10.6
335	151.95	265.9	3	10.6
336	152.41	266.7	3	10.7
337	152.86	267.5	3	10.7
338	153.31	268.3	3	10.7
339	153.77	269.1	3	10.8
340	154.22	269.9	3	10.8
341	154.67	270.7	3	10.8
342	155.13	271.5	3	10.9
343	155.58	272.3	3	10.9
344	156.04	273.1	3	10.9
345	156.49	273.9	3	11.0
346	156.94	274.6	3	11.0
347	157.40	275.4	3	11.0
348	157.85	276.2	3	11.0
349	158.30	277.0	3	11.1
350	158.76	277.8	3	11.1
351	159.21	278.6	3	11.1
352	159.66	279.4	3	11.2
353	160.12	280.2	3	11.2
354	160.57	281.0	3	11.2
355	161.03	281.8	3	11.3
356	161.48	282.6	3	11.3
357	161.93	283.4	3	11.3
358	162.39	284.2	3	11.4
359	162.84	285.0	3	11.4
360	163.29	285.8	3	11.4

*Rounded to the nearest hundredth decimal place.

†Rounded to the nearest tenth decimal place.

Total doses exceeding 300 mg per infusion are not recommended for the 1.75-mg/kg maintenance dose in adults with PsA, AS, or nr-axSpA.

COSENTYX IV formulation may be administered with or without a loading dose.

In using this guide, you are agreeing to the following: This guide is intended for use by qualified healthcare providers only and is not a substitute for clinical judgment. Novartis Pharmaceuticals Corporation makes no claims pertaining to the accuracy of the information contained within the guide. All calculations should be confirmed prior to administration of COSENTYX for IV use. Neither Novartis Pharmaceuticals Corporation nor any party involved in the creation of this website is liable to you or others for any actions taken or decisions made in reliance on this guide.

Please see Indications and Important Safety Information on page 8.

Please see full Prescribing Information, including Medication Guide.

Maintenance dose calculations[1] (cont)

Please see Preparation and Administration of COSENTYX® for Intravenous Use under the DOSAGE AND ADMINISTRATION section in the full Prescribing Information.

Cosentyx® (secukinumab)

Weight (lb)	Weight (kg) (lb x 0.453592)*	Total dose (mg) (kg x 1.75 mg/kg)†	Number of single-use vials required	Total volume to be withdrawn (mL) (Total dose x 5 mL/125 mg)†
361	163.75	286.6	3	11.5
362	164.20	287.4	3	11.5
363	164.65	288.1	3	11.5
364	165.11	288.9	3	11.6
365	165.56	289.7	3	11.6
366	166.01	290.5	3	11.6
367	166.47	291.3	3	11.7
368	166.92	292.1	3	11.7
369	167.38	292.9	3	11.7
370	167.83	293.7	3	11.7
371	168.28	294.5	3	11.8
372	168.74	295.3	3	11.8
373	169.19	296.1	3	11.8
374	169.64	296.9	3	11.9
375	170.10	297.7	3	11.9
376	170.55	298.5	3	11.9
377	171.00	299.3	3	12.0

*Rounded to the nearest hundredth decimal place.

†Rounded to the nearest tenth decimal place.

Total doses exceeding 300 mg per infusion are not recommended for the 1.75-mg/kg maintenance dose in adults with PsA, AS, or nr-axSpA.

COSENTYX IV formulation may be administered with or without a loading dose.

In using this guide, you are agreeing to the following: This guide is intended for use by qualified healthcare providers only and is not a substitute for clinical judgment. Novartis Pharmaceuticals Corporation makes no claims pertaining to the accuracy of the information contained within the guide. All calculations should be confirmed prior to administration of COSENTYX for IV use. Neither Novartis Pharmaceuticals Corporation nor any party involved in the creation of this website is liable to you or others for any actions taken or decisions made in reliance on this guide.

Reference: 1. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.

Please see Indications and Important Safety Information on page 8.
Please see full Prescribing Information, including Medication Guide.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.

COSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in patients 2 years of age and older.

COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis (AS).

COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX. Cases of anaphylaxis have been reported during treatment with COSENTYX.

WARNINGS AND PRECAUTIONS

Infections

COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in COSENTYX treated subjects compared to placebo-treated subjects. In placebo-controlled clinical trials in subjects with moderate to severe plaque psoriasis, higher rates of common infections, such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%) and mucocutaneous infections with candida (1.2% versus 0.3%) were observed with COSENTYX compared with placebo. A similar increase in risk of infection was seen in placebo-controlled trials in subjects with psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. The incidence of some types of infections appeared to be dose-dependent in clinical studies. In the postmarketing setting, serious and some fatal infections have been reported in patients receiving COSENTYX.

Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection.

Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves.

Pre-treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Avoid administration of COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients closely for signs and symptoms of active TB during and after treatment.

Inflammatory Bowel Disease

Caution should be used when prescribing COSENTYX to patients with inflammatory bowel disease. Exacerbations, in some cases serious, occurred in COSENTYX treated subjects during clinical trials in plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. In addition, new onset inflammatory bowel disease cases occurred in clinical trials with COSENTYX. In an exploratory trial in 59 subjects with active Crohn's disease, there were trends toward greater disease activity and increased adverse events in the secukinumab group as compared to the placebo group. Patients who are treated with COSENTYX should be monitored for signs and symptoms of inflammatory bowel disease.

Eczematous Eruptions

In postmarketing reports, cases of severe eczematous eruptions, including atopic dermatitis-like eruptions, dyshidrotic eczema, and erythroderma, were reported in patients receiving COSENTYX; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of COSENTYX.

Treatment may need to be discontinued to resolve the eczematous eruption. Some patients were successfully treated for eczematous eruptions while continuing COSENTYX.

Hypersensitivity Reactions

Anaphylaxis and cases of urticaria occurred in COSENTYX treated subjects in clinical trials. If an anaphylactic or other serious allergic reaction occurs, administration of COSENTYX should be discontinued immediately and appropriate therapy initiated.

The removable caps of the COSENTYX Sensoready® pen and the COSENTYX 1 mL and 0.5 mL prefilled syringes contain natural rubber latex, which may cause an allergic reaction in latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.

Immunizations

Prior to initiating therapy with COSENTYX, consider completion of all age appropriate immunizations according to current immunization guidelines. COSENTYX may alter a patient's immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX.

MOST COMMON ADVERSE REACTIONS

Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.

Please see full Prescribing Information, including Medication Guide.

NOVARTIS

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080